Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women

References

• BaronRTsouderosY2002In vitro effects of S12911–2 on osteoclast function and bone marrow macrophage differentiationEur J Pharmacol450111712176103
   PubMed Web of Science ®Google Scholar
• BekkerPJHollowayDLRasmussenAS2004A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal womenJ Bone Miner Res20227582
   Web of Science ®Google Scholar
• BeralVMillion Women Study Colloborators2003Breast cancer and hormone-replacement therapy in the Million Women StudyLancet362116014550719
   PubMed Web of Science ®Google Scholar
• BlackDMBilezikianJPEnsrudKE2005One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosisN Engl J Med3535556516093464
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDB1996Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet3481535418950879
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKE2003The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med34912071514500804
   PubMed Web of Science ®Google Scholar
• BoneHGHoskingDDevogelaerJP2004Ten years’experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med35011899915028823
   PubMed Web of Science ®Google Scholar
• BurgeRT2001The cost of osteoporotic fractures in the UK. Projections for 2000–2020J Med Econ45162
   Google Scholar
• CauleyJARobbinsJChenZ2003Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trialJAMA29017293814519707
   PubMed Web of Science ®Google Scholar
• CenterJRNguyenTVSchneiderD1999Mortality after all major types of osteoporotic fracture in men and women: an observational studyLancet3538788210093980
   PubMed Web of Science ®Google Scholar
• ChestnutCH3rdMcClungMREnsrudKE1995Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelingAm J Med99144527625419
   PubMed Web of Science ®Google Scholar
• ChestnutCHEttingerMPMillerPD2005Ibandronate produces significant, similar efficacy in North American and European women: new clinical findings from BONECurr Med Res Opin2139140115811208
   PubMed Web of Science ®Google Scholar
• ChristiansenCRiisBJ199017 Beta-estradiol and continuous norethister-one: a unique treatment for established osteoporosis in elderly womenJ Clin Endocrinol Metab71836412205624
   PubMed Web of Science ®Google Scholar
• CosmanFBaz-HechtMCushmanM2005Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literatureThromb Res11611315850603
   PubMed Web of Science ®Google Scholar
• CramerJAAmonkarMMHebbornA2005Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin2114536016197664
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDE1998Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA2802119209875882
   PubMed Web of Science ®Google Scholar
• DealCL2002Risedronate prevents hip fractures, but who should get therapy?Cleve Clin J Med699647612546269
   PubMed Web of Science ®Google Scholar
• DelmasPDBjarnasonNHMitlakBH1997Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med337164179385122
   PubMed Web of Science ®Google Scholar
• DelmasPDGenantHKCransGG2003Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trialBone335223214555255
   PubMed Web of Science ®Google Scholar
• DolanPTorgersonDJ1998The cost of treating osteoporotic fractures in the United Kingdom female populationOsteoporos Int86111710326069
   PubMed Web of Science ®Google Scholar
• EastellRBartonIHannonRA2003Relationship of early changes in bone resorption to the reduction in fracture risk with risedronateJ Bone Miner Res181051612817758
   PubMed Web of Science ®Google Scholar
• EnsrudKEBlackDMPalermoL1997Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention TrailArch Intern Med1572617249531231
   PubMed Web of Science ®Google Scholar
• EttingerBBlackDMMitlakBH1999Reduction of vertebral fracture risk in postmenopausal women treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA2826374510517716
   PubMed Web of Science ®Google Scholar
• GonnelliSCepollaroCPondrelliC1997The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosisJ Bone Miner Res12624319101374
   PubMed Web of Science ®Google Scholar
• HarrisSTGertzBJGenantHK1993The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal womenJ Clin Endocrinol Metab7613998501142
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHK2000Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA28314245
   Google Scholar
• HeaneyRPZizicTMFogelmanI2002Risedronate reduces the risk of first vertebral fracture in osteoporotic womenOsteoporos Int13501512107665
   PubMed Web of Science ®Google Scholar
• HoskingDChilversCEChristiansenC1998Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study GroupN Engl J Med338485929443925
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellOOdenA2000Long-term risk of osteoporotic fracture in MalmoOsteoporos Int116697411095169
   PubMed Web of Science ®Google Scholar
• KarpfDBShapiroDRSeemanE1997Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study GroupsJAMA2771159649087473
   PubMed Web of Science ®Google Scholar
• KimSWPark doJParkKS2005Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in korean postmenopausal women with osteoporosisEndocr J526677416410657
   PubMed Web of Science ®Google Scholar
• LaytonDClarkeAWiltonLV2005Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring studyOsteoporos Int1649050015309382
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBrollJ1995Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med33314377477143
   PubMed Web of Science ®Google Scholar
• LufkinEGWahnerHWO’FallonWM1992Treatment of post-menopausal osteoporosis with transdermal estrogenAnn Intern Med117191534476
   PubMed Web of Science ®Google Scholar
• LufkinEGWhitakerMDNickelsenT1998Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trialJ Bone Miner Res131747549797484
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPD2001Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med3443334011172164
   PubMed Web of Science ®Google Scholar
• MeunierPJRouxCSeemanE2004The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med3504596814749454
   PubMed Web of Science ®Google Scholar
• MeunierPJSlosmanDODelmasPD2002Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trialJ Clin Endocrinol Metab872060611994341
   PubMed Web of Science ®Google Scholar
• MeunierPJVignotEGarneroP1999Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study GroupOsteoporos Int10330610692984
   PubMed Web of Science ®Google Scholar
• MillerPDMcClungMRMacoveiL2005Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE studyJ Bone Miner Res2013152216007327
   PubMed Web of Science ®Google Scholar
• MillerPDWattsNBLicataAA1997Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatmentAm J Med103468769428829
   PubMed Web of Science ®Google Scholar
• NielsenSPSlosmanDSorensenOH1999Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometryJ Clin Densitom2371910677790
   PubMed Web of Science ®Google Scholar
• PolsHAFelsenbergDHanleyDA1999Multinational, placebo-controlled trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study GroupOsteoporos Int9461810550467
   PubMed Web of Science ®Google Scholar
• RavnPHoskingDThompsonD1999Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort studyJ Clin Endocrinol Metab842363810404804
   PubMed Web of Science ®Google Scholar
• ReckerRLappeJDaviesKM2004Bone remodelling increases substantially in the years after menopause and remains increased in older osteoporosis patientsJ Bone Miner Res1916283315355557
   PubMed Web of Science ®Google Scholar
• ReckerRRDaviesKMDowdRM1999The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trialAnn Intern Med13089790410375338
   PubMed Web of Science ®Google Scholar
• ReginsterJSeemanEVernejoulM2005Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: TROPOS studyJ Clin Endocrinol Metab9028162215728210
   PubMed Web of Science ®Google Scholar
• ReginsterJYAdamiSLakatoaP2006Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE studyAnn Rheum Dis656546116339289
   PubMed Web of Science ®Google Scholar
• ReginsterJYDeroisyRDougadosM2002Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo controlled PREVOS trialOsteoporos Int139253112459934
   PubMed Web of Science ®Google Scholar
• ReidIRBrownJPBurckhardtP2002Intravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med3466536111870242
   PubMed Web of Science ®Google Scholar
• ReskaAARodanGA2004Nitrogen-containing bisphosphonate mechanism of actionMini Rev Med Chem47111915379639
   PubMed Web of Science ®Google Scholar
• ReskaAARodanGA2003Mechanism of action of bisphosphonatesCurr Osteoporos14552
   Google Scholar
• RodanGAFleischHA1996Bisphosphonates: mechanisms of actionJ Clin Invest97269268675678
   PubMed Web of Science ®Google Scholar
• RogersMJ2003New insights into the molecular mechanisms of action of bisphosphonatesCurr Pharm Des926435814529538
   PubMedGoogle Scholar
• RomeroAAlonsoCRinconM2005Risk of venous thromboembolic in women. A qualitative systematic reviewEur J Obstet Gynecol Reprod Biol12181715950363
   PubMed Web of Science ®Google Scholar
• RossPD1997Clinical consequences of vertebral fracturesAm J Med10330S42S9302895
   PubMedGoogle Scholar
• SebbaAIBonnickSLKaganR2004Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35mg in the treatment of postmenopausal osteoporosisCurr Med Res Opin2020314115706659
   PubMed Web of Science ®Google Scholar
• SmallRE2005Uses and limitations of bone mineral density measurements in the management of osteoporosisMedGenMed9316369382
   PubMedGoogle Scholar
• SorensenOHCrawfordGMMulderH2003Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experienceBone32120612633783
   PubMed Web of Science ®Google Scholar
• Ste-MarieLGSodEJohnsonT2004Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosisCalcif Tissus Int7546976
   PubMed Web of Science ®Google Scholar
• StroupGBLarkMWVeberDF2001Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primateJ Bone Miner Res1617394611585335
   PubMed Web of Science ®Google Scholar
• TakahashiNSasakiTTsouderosY2003S12911-2 inhibits osteoclastic bone resorption in vitroJ Bone Miner Res181082712817762
   PubMed Web of Science ®Google Scholar
• TucciJRToninoRPEmkeyRD1996Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosisAm J Med1014888948272
   PubMed Web of Science ®Google Scholar
• WattsNBWorleyKSolisA2004Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims databaseJ Manag Care Pharm101425115032563
   PubMedGoogle Scholar
• WeinsteinRSParfittAMMarcusR2003Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal womenOsteoporos Int148142214610642
   PubMed Web of Science ®Google Scholar